GSK plc (LON:GSK) Insider Purchases £99,671 in Stock

GSK plc (LON:GSK) insider Jonathan Symonds acquired 7,150 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of GBX 1,394 ($18.08) per share, for a total transaction of £99,671 ($129,258.20).

GSK Stock Down 1.0 %

Shares of GSK stock opened at GBX 1,392.50 ($18.06) on Friday. The firm’s fifty day moving average price is GBX 1,545.31 and its two-hundred day moving average price is GBX 1,594.75. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. GSK plc has a 1 year low of GBX 1,371.40 ($17.78) and a 1 year high of GBX 1,823.50 ($23.65). The firm has a market capitalization of £56.81 billion, a P/E ratio of 1,232.30, a PEG ratio of 1.24 and a beta of 0.31.

GSK Dividend Announcement

The business also recently announced a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK’s payout ratio is presently 5,309.73%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GSK shares. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Monday, July 29th. Citigroup cut their price target on shares of GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a “buy” rating on the stock in a research note on Friday, July 5th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,850 ($23.99) price target on shares of GSK in a report on Tuesday, September 3rd. Shore Capital restated a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,820 ($23.60) target price on shares of GSK in a research note on Tuesday, September 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,842.50 ($23.89).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.